Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
861-880 of 991 trials

Advanced Ovarian Cancer: Relacorilant with Nab-Paclitaxel and Bevacizumab

We are studying a new treatment combination for patients with advanced ovarian, primary peritoneal, or fallopian-tube cancer. The trial aims to evaluate how well this combination works and its safety.

Ovarian, Fallopian Tube, or Peritoneal CancerEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Intranasal Lysine-Aspirin for Respiratory Disease

We are studying the effects of a new nasal treatment on asthma and nasal symptoms in patients with NSAID-exacerbated respiratory disease. The goal is to see if it improves breathing and overall quality of life.

Nonsteroidal Anti-Inflammatory Drug Exacerbated Respiratory Disease (N-ERD)1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Congenital Nephrogenic Diabetes Insipidus: Fluconazole Study

We are testing whether fluconazole can help people with congenital nephrogenic diabetes insipidus reduce excessive urination and improve their quality of life. This study focuses on patients with a specific AVPR2 gene mutation.

Congenital Nephrogenic Diabetes Insipidus≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrology

Chronic Obstructive Pulmonary Disease: Tezepelumab Study

We are investigating whether tezepelumab can help adults with moderate to very severe COPD experience fewer flare-ups and improve their lung function and quality of life compared to a placebo.

Chronic Obstructive Pulmonary Disease (COPD)1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementPartially RemotePulmonology

Alcohol Use Disorder: Psilocybin Treatment

We are studying if a single dose of psilocybin can help reduce heavy drinking in people with alcohol use disorder. This trial compares the effects of psilocybin to a placebo over 12 weeks.

Alcohol Use Disorder>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Duchenne Muscular Dystrophy: ENTR-601-45 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and well-tolerated. This study will help us understand how the treatment works in the body.

Duchenne Muscular Dystrophy6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Chronic Inflammatory Demyelinating Polyneuropathy: DNTH103 Treatment Study

We are studying a new treatment called DNTH103 for adults with Chronic Inflammatory Demyelinating Polyneuropathy. The trial aims to see if it can help reduce relapses and improve overall health compared to a placebo.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Neovascular Age-Related Macular Degeneration: Faricimab Injections

We are studying the safety and long-term effectiveness of faricimab injections for people with neovascular age-related macular degeneration. The goal is to see if it improves vision and how well it works over time.

Neovascular Age-Related Macular Degeneration>2 yearsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOphthalmology

ALK-Positive Advanced Lung Cancer: NVL-655 vs. Alectinib

We are studying a new medication, NVL-655, for patients with advanced ALK-positive lung cancer who haven't been treated before. The goal is to see if it works better and is safer than the current standard treatment, alectinib.

Advanced ALK-positive Non-Small Cell Lung CancerConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Duchenne Muscular Dystrophy: ENTR-601-44 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and how it affects muscle function. Participants will receive either the treatment or a placebo in a controlled setting.

Duchenne Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Hidradenitis Suppurativa: Ruxolitinib Cream Study

We are evaluating a new cream for people with hidradenitis suppurativa to see if it helps reduce symptoms and is safe to use. This study aims to find out how effective the cream is compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementDermatology

Knee Cartilage Damage: UC-MSC Treatment

We are studying a new treatment using stem cells from umbilical cord tissue for people with cartilage damage in the knee. The trial aims to evaluate the safety and effectiveness of this approach.

Knee Cartilage Defect1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Ataxia-Telangiectasia: N-Acetyl-L-Leucine Study

We are studying whether N-Acetyl-L-Leucine can improve symptoms and quality of life for people with Ataxia-Telangiectasia. The trial will also assess the safety of this treatment.

Ataxia Telangiectasia3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Dexamethasone for Severe Burns

We are studying whether early treatment with dexamethasone can help reduce serious complications and death in patients with severe burns. This trial will also look at its effects on infections and recovery times.

Severe Burns3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

COVID-19: Ibuzatrelvir Study for High-Risk Patients

We are investigating whether ibuzatrelvir can help reduce symptoms and prevent severe illness in non-hospitalized adults and adolescents with COVID-19. This study compares the medication to a placebo to see how effective it is.

COVID-193-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal Medicine

Lower Limb Nonunion: NVD-003 Implant Study

We are testing a new 3D bone implant for adults with nonunion fractures in the lower limb. The study aims to evaluate its safety and effectiveness in promoting healing and improving quality of life.

Recalcitrant Lower Limb Nonunion1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and Traumatology

Lung Cancer Treatment: Rilvegostomig vs. Pembrolizumab

We are studying a new drug, rilvegostomig, to see if it works better than pembrolizumab for patients with PD-L1-high metastatic non-small cell lung cancer. This trial aims to understand which treatment may improve survival and quality of life.

Lung CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Crohn's Disease: New Cellular Treatment for Fistulas

We are studying a new injection of fat-derived cells for people with complex perianal Crohn's fistulas. The goal is to see if this treatment helps heal fistulas better than a placebo.

Crohn's Disease>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Hemophilia A: Efanesoctocog Alfa Treatment Study

We are studying the long-term effects of efanesoctocog alfa on joint health in people with hemophilia A. The trial aims to see how well it prevents joint bleeds and improves quality of life.

Haemophilia A1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOrthopedics and Traumatology

Moderate-to-Severe Asthma: PF-07275315 Study

We are investigating a new medication called PF-07275315 for adults with moderate-to-severe asthma. The study aims to see if it is more effective than a placebo in improving asthma control and quality of life.

Moderate-to-Severe Asthma6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementAllergologyPulmonology